By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Expedeon and Protein Discovery today announced that they have signed a merger agreement.

Under the terms of the deal, the new company will keep the Expedeon name and remain headquartered in Cambridge, UK. Heikki Lanckriet, founder and CEO of Expedeon, will be the CEO of the new firm. Chuck Witkowski, founder and CEO of Protein Discovery, will join Expedeon's board of directors, the firms said.

Financial terms of the deal were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A panel at the New York Times discusses anonymity and privacy of users of 23andMe's services when access to its database is offered for research.

National Institutes of Health Director Francis Collins appears before a House subcommittee to discuss his agency's budget request.

In PNAS this week: Akt3 amplification in glioma progression, Tibetan Plateau frog genome, and more.

The US Supreme Court has declined to review a decision involving the use of "inadvertently shed" DNA in a police investigation and subsequent conviction.

Mar
05
Sponsored by
SomaLogic

In this live webcast, Robert Gerszten of Massachusetts General Hospital will describe an ongoing project that is integrating metabolic and proteomic profiling to gain a better understanding of cardiometabolic disease.